F. van Leth

Latest

• Relative cost of multidrug-resistant TB medicines in Europe.
• Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
• Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV
• Use and impact of molecular methods for detecting drug-resistant TB.
• "A false sense of confidence" The perceived role of inflammatory point-of-care testing in managing urinary tract infections in Dutch nursing homes: a qualitative study.
• Management of patients with multidrug-resistant tuberculosis
• Treatment responses in multidrug-resistant tuberculosis in Germany
• Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda
• Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania
• Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012
• Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
• Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey
• Implementation of tuberculosis infection prevention and control in Mozambican health care facilities
• Validation of indirect tuberculosis treatment adherence measures in a resource-constrained setting
• The tuberculin skin test: a comparison of ruler and calliper readings
• National anti-tuberculosis drug resistance study in Tanzania
• Projection of the number of patients with tuberculosis in the Netherlands in 2030
• Annual meeting of the Tuberculosis Surveillance and Research Unit, 2008
• Inclusion of information on risk factors, socio-economic status and health seeking in a tuberculosis prevalence survey
• Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study
• [Practice guideline prevention, diagnosis and treatment of tuberculosis in patients with an HIV infection]
• Implementation of a national anti-tuberculosis drug resistance survey in Tanzania
• Organisation of a tuberculosis prevalence survey
• Tuberculosis prevalence surveys: rationale and cost
• Measuring tuberculosis burden, trends, and the impact of control programmes
• Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data
• [Estimation of the incidence of tuberculosis in The Netherlands in 2030]
• Assessment of patient preference in allocation and observation of anti-tuberculosis medication in three districts in Tanzania
• Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule
• Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response
• Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents
• Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
• [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]
• Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort
• Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study
• Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens
• Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children
• Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy
• The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
• Are adverse events of nevirapine and efavirenz related to plasma concentrations?
• Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study
• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
• Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz
• Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
• Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy
• Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
• Use of composite end points to measure clinical events
• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
• Identifying malnourished children may not be easy
• Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile